Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB:RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
Related news for (RDGL)
- Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™
- Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
- Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
- Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
- Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial